Aspira Women's Health Inc. (AWHL): Nasdaq/NYSE listing notice — Aspira Women's Health receives Nasdaq delisting notice for failure to meet equity minimum

Aspira Women's Health Inc.

Received written notice on April 15, 2025 that Nasdaq Hearings Panel determined to delist shares due to non-compliance with Listing Rule 5550(b)(1).
Company failed to maintain minimum $2.5 million in stockholders' equity for continued listing on Nasdaq Capital Market.
Trading suspension on Nasdaq effective at open of trading on April 17, 2025.
Common stock expected to begin trading on OTC Markets under symbol AWH following suspension.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Aspira Women's Health Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: stockholders equity
Rules: 5550(b)(1)

Exact text from the filing

April 15, 2025, Aspira Women’s Health Inc. (the “Company) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The Notice indicated t

View on SEC.gov

2 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-005086

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.